Shares of ReShape Lifesciences Inc. (RSLS) are down over 55% at $0.71 in premarket trading today after an eye-popping 340% surge yesterday.
In an SEC filing yesterday, ReShape Lifesciences announced that it is unable to file its Form 10-K for the year ended December 31, 2024, on time without unreasonable effort or cost, as it requires additional time to complete the compilation of information. The company expects to file the Form 10-K within the extended period allowed by Rule 12b-25 of the Securities Exchange Act of 1934, which provides an additional 15 calendar days to submit a late 10-K.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.